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Oxford, United Kingdom
This issue of the Journal includes an important new analysis
of the TRACE (TRAndolapril Cardiac Evaluation) data-
base that was set up to identify eligible patients for the
subsequent randomized trial of angiotensin-converting en-
zyme (ACE) inhibition in acute myocardial infarction (MI)
(1). This database is unique in that the TRACE investiga-
tors identified and followed up an unusually high proportion
of all cases of MI occurring in Denmark in 1990 to 1992.
All the 27 coronary care units were the only units in their
respective regions, and so this survey produces a reliable
snapshot of clinical practice.
The collaborators collected clinical, electrocardiogram
(ECG) and echocardiographic data on all of approximately
6,500 patients admitted to the hospital with enzymatically
determined acute MI, and then obtained follow-up data on
stroke and survival. The decision to use thrombolytic
therapy was left to the judgment of their physicians, with no
set criteria beyond the general consensus at the time. Forty
percent received lytic therapy, a reasonable figure by inter-
national standards. Ninety-five percent received streptoki-
nase as the lytic agent. The present investigation retrospec-
tively examined these decisions in the light of the first
Fibrinolytic Therapy Trialists (FTT) collaborative group,
published two years after the original Danish survey (2).
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In this issue of the Journal, Ottesen et al. (3) judged
whether the earlier decisions on the utilization of thrombo-
lytics were appropriate, both for overutilization of lytic
therapy in the 40% who received it, and for underutilization
in the remainder who were not given it. Mortality follow up
was to mid-1998; only 39 patients lacked survival data.
These data are now particularly relevant in view of the
recent analysis of the U.S. Medicare database, which sug-
gested that thrombolytic therapy may be harmful in patients
.75 years with acute MI (4).
In the U.S., tissue plasminogen activator (tPA) is the
predominant choice in view of the GUSTO-I results,
whereas European practice—especially eight years ago—
favored streptokinase because of its much lower cost, and
perhaps because of the lack of evidence of superiority for
tPA in the non-North American patients enrolled in
GUSTO-I (about half the study population) (5). Unlike the
recent Medicare experience, the current analysis finds no
evidence of adverse effects in older patients, especially for
stroke.
The mortality (in those receiving thrombolysis) was lower
even in those with a prior history of stroke, a contraindica-
tion (i.e., overutilization of thrombolysis). Using the benefit
of hindsight, the authors found that there was a substantial
“inappropriate” use of lytic therapy. Of the 2,781 patients
who had a conventional indication but no contraindications,
66% received it, which is commendably high by many
national surveys, in which underuse is even higher. Sixty
percent had no indications, or at least one contraindication
or both, but 851 of these 3,811 patients were actually given
lytic therapy (i.e., overutilization). Of these, 620 patients
had no conventional indication—usually because of hospital
admission .12 h from onset (60%) or no ST elevation
(55%). The most common contraindication was a prior
history of stroke (52%), or ulcer (9%). No cases of uncon-
trolled hypertension were treated. Ninety-nine of 540 (18%)
patients with prior stroke actually received lytic therapy; in
these, the hospital incidence of stroke was reassuringly low
at 1.0% and certainly not higher than in those not treated,
of whom 1.7% experienced a stroke; but patients who did
get lytic therapy (in this nonrandomized comparison) had a
lower risk profile.
The authors are careful and correct to point out that in
their analysis of this observational but nonrandomized data,
one can only draw tentative conclusions. I agree with their
comment that thrombolysis is underused not only in entirely
eligible patients (where underutilization is between 30% and
50% in many surveys), but it is also underused in high risk
patients with conventional contraindications, such as prior
stroke or peptic ulcer, perhaps in the remote past. They
conclude that their data show that ordinary physicians are
able to balance these risks and select such patients so that
the risk is acceptable.
The value of these new data is to contrast real life with
clinical trials. The latter always enroll fitter and often
younger patients than the “garden” variety seen in district
hospitals. Important risks, such as cerebral hemorrhage, are
underestimated in trials.
I believe that these data, when contrasted with the
Medicare database (4), once more raise questions about the
safety in elderly patients of more aggressive agents such as
tPA and of more aggressive regimens of tPA. Unpublished
but widely circulated data from the FTT overview showed
an increasing incidence of intracranial hemorrhage with
increasing age for tPA compared with streptokinase, which
reached a fourfold to fivefold greater incidence in the oldest
age group. Even without lytic therapy, there is an increased
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risk of stroke with increasing age; however, the absolute
benefit of thrombolysis is greater in the elderly (2).
In the past, we have criticized the prevailing U.S. view of
the superiority of tPA over streptokinase in terms of its
mortality benefit (6,7), and the greater safety of streptoki-
nase, especially in the old.
We agree with the authors of the present analysis and
those of the recent Medicare analysis that there is a pressing
need for new randomized trials of thrombolysis in elderly
patients. I would add that it would be worthwhile to revisit
GUSTO-I in an elderly population, taking care not to
discontinue streptokinase therapy when symptomless hypo-
tension occurs—this may, in fact, partly explain the lower
incidence of cerebral hemorrhage with the older, cheaper
streptokinase and the apparent superiority of tPA in
GUSTO-I.
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